- ISIN
- CA74764Y2050
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 8, 2018
Highlights
- Market Cap
- $22.94M
- Enterprise Value
- $20.33M
- EPS (TTM)
- -$8.16
- Gross Profit (TTM)
- -$400.75K
- EBITDA (TTM)
- -$18.93M
- Year Range
- $2.07 - $38.25
- ROA (TTM)
- -207.13%
- ROE (TTM)
- -5,193.98%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
QNTM Performance Chart
Quantum BioPharma Ltd (QNTM) is down 30.0% since the beginning of the year. At $5 per share, QNTM is trading 86.6% below its 52-week high of $38. Investors who bought $1,000 worth of QNTM shares 5 years ago would now be looking at an investment worth $37.
Loading charts...
Returns By Period
Quantum BioPharma Ltd (QNTM) has returned -30.00% so far this year and -66.38% over the past 12 months.
Quantum BioPharma Ltd
- 1D
- -2.67%
- 1M
- -7.93%
- YTD
- -30.00%
- 6M
- -47.32%
- 1Y
- -66.38%
- 3Y*
- -59.91%
- 5Y*
- -48.31%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
QNTM Monthly Returns History
Based on dividend-adjusted daily data since Jun 8, 2018, QNTM's average daily return is +0.05%, while the average monthly return is -1.18%.
Historically, 35% of months were positive and 65% were negative. The best month was Sep 2018 with a return of +184.6%, while the worst month was Oct 2019 at -55.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.
On a daily basis, QNTM closed higher 42% of trading days. The best single day was Jun 3, 2020 with a return of +138.4%, while the worst single day was Aug 12, 2024 at -35.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -37.26% | -22.49% | 36.06% | 18.63% | 19.72% | -25.51% | -30.00% | ||||||
| 2025 | -15.49% | 46.30% | 69.45% | -15.56% | 106.76% | 50.45% | 15.90% | -28.21% | -2.67% | -32.50% | -12.38% | -24.74% | 98.37% |
| 2024 | -9.22% | 4.20% | -17.76% | -43.05% | -26.38% | -46.00% | -37.65% | -31.00% | -11.70% | 18.25% | -1.27% | -21.20% | -93.84% |
| 2023 | 35.72% | 64.49% | -11.93% | -3.87% | -28.19% | 7.48% | 1.74% | 10.26% | -6.16% | -14.09% | 0.96% | -12.40% | 16.67% |
| 2022 | -13.73% | 19.32% | -17.53% | 16.64% | -2.99% | -19.37% | 13.92% | 1.01% | -9.25% | 3.01% | -0.21% | -7.03% | -22.71% |
| 2021 | 28.85% | 2.49% | -7.28% | -5.76% | -1.67% | -1.69% | 0.57% | 4.57% | -13.66% | -12.03% | -13.67% | -15.00% | -34.62% |
Benchmark Metrics
Quantum BioPharma Ltd has an annualized alpha of -2.41%, beta of 1.11, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since June 11, 2018.
- This stock participated in 120.29% of S&P 500 Index downside but only -84.10% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -2.41%
- Beta
- 1.11
- R²
- 0.02
- Upside Capture
- -84.10%
- Downside Capture
- 120.29%
Return for Risk
Risk / Return Rank
QNTM ranks 24 for risk / return — below 24% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Quantum BioPharma Ltd (QNTM) and compare them to S&P 500 Index.
| QNTM | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.42 | 2.39 | -2.80 |
Sortino ratioReturn per unit of downside risk | 0.12 | 3.25 | -3.14 |
Omega ratioGain probability vs. loss probability | 1.01 | 1.43 | -0.42 |
Calmar ratioReturn relative to maximum drawdown | -0.71 | 3.11 | -3.82 |
Martin ratioReturn relative to average drawdown | -0.95 | 14.38 | -15.33 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Quantum BioPharma Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Quantum BioPharma Ltd was 99.98%, occurring on Mar 11, 2026. The portfolio has not yet recovered.
The current Quantum BioPharma Ltd drawdown is 99.94%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.98%Mar 2026 | 7y 5mo | — | 7y 8moSep 2018 - now |
2018 bear market2018 | -33.33%Aug 2018 | 1mo 11d | 16d | 1mo 27dJul 2018 - Aug 2018 |
Rate-hike selloffLate 2018 | -24.14%Sep 2018 | 2d | 6d | 8dSep 2018 - Sep 2018 |
2018 correction2018 | -16.11%Jun 2018 | 1d | 5d | 6dJun 2018 - Jul 2018 |
2018 correction2018 | -13.95%Jun 2018 | 1d | 7d | 8dJun 2018 - Jun 2018 |
Drawdown Indicators
| QNTM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -56.78% | -43.20% |
Max Drawdown (1Y)Largest decline over 1 year | -94.00% | -9.10% | -84.90% |
Max Drawdown (3Y)Largest decline over 3 years | -97.98% | -18.90% | -79.08% |
Max Drawdown (5Y)Largest decline over 5 years | -98.42% | -25.43% | -72.99% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.94% | 0.00% | -99.94% |
Average DrawdownAverage peak-to-trough decline | -92.22% | -10.72% | -81.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 69.73% | 1.97% | +67.76% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Quantum BioPharma Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Quantum BioPharma Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for QNTM in comparison with other companies in the Biotechnology industry. Currently, QNTM has a P/B value of 38.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with QNTM
Add Quantum BioPharma Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with QNTM